Cardiovascular

Post-MI secondary prevention and discharge medication bundle

Clinical Overview and When to Suspect Inadequate Post-MI Secondary Prevention

— Post-MI patients carry a ~5–10% annual risk of recurrent MACE (death, reinfarction, stroke, heart failure) without optimal medical therapy

— Up to 25% of recurrent events occur within the first year; risk is highest in the first 30–90 days post-discharge

— Adherence to the full discharge bundle reduces 1-year mortality by ~30–40% vs. partial therapy

— A: Antiplatelets (aspirin + P2Y12), ACE inhibitor/ARB, Aldosterone antagonist (if indicated)

— B: Beta-blocker, Blood pressure target

— C: Cholesterol (high-intensity statin ± ezetimibe/PCSK9), Cigarette cessation, Cardiac rehab

— D: Diet/Diabetes control (SGLT2i/GLP-1 RA if T2DM or HFrEF)

— E: Exercise, Education, Ejection fraction reassessment

— Patient post-MI presenting at 6-week follow-up still on only aspirin and a low-dose statin

— Recent NSTEMI discharged without P2Y12 inhibitor or beta-blocker due to "soft" contraindications

— Diabetic post-MI not on SGLT2 inhibitor despite preserved renal function

— LDL >70 mg/dL at any post-MI visit — intensify therapy, do not "watch"

Scope of the problem

The "ABCDE" Step 3 mental model for post-MI

When to suspect undertreatment (high-yield Step 3 vignette triggers)

Step 3 management: The post-MI discharge encounter is itself a graded transition-of-care item. Before signing the discharge order set on CCS, confirm the GDMT bundle, schedule cardiology follow-up within 2–4 weeks, and refer to cardiac rehab — missing rehab referral is a common test trap and a measurable quality metric (CMS).

Board pearl: Secondary prevention applies to all MI types (STEMI, NSTEMI, type 2 MI with atherosclerotic substrate). Type 2 MI from demand ischemia in fixed CAD still warrants the bundle; pure supply/demand mismatch without CAD (e.g., severe anemia, sepsis) does not automatically trigger DAPT but still merits statin and risk-factor modification.

Presentation Patterns and Key History at the Post-MI Visit

— Review index event details: STEMI vs NSTEMI, culprit vessel, stent type (DES vs BMS), residual disease, peak troponin, LVEF on discharge echo

— Confirm revascularization completeness: was PCI complete or staged? Any planned procedures?

— Document bleeding history, prior stroke, PUD, anemia — drives DAPT duration and antiplatelet choice

— Angina recurrence: new exertional chest pain suggests in-stent restenosis, stent thrombosis (early), or progression of nontreated lesions

— Dyspnea/orthopnea/edema: emerging HFrEF — triggers repeat echo at 40 days

— Palpitations/syncope: post-MI VT, AV block, or new AF

— Depression screening (PHQ-9): post-MI depression doubles mortality — screen at every visit in the first year

— Verify each bundle component is filled and taken; ask specifically about cost barriers (P2Y12 inhibitors and PCSK9i are common nonadherence triggers)

— Ask about OTC NSAIDs — interact with aspirin and increase bleeding/MI risk

— Confirm no PPI–clopidogrel issue if applicable (omeprazole/esomeprazole reduce clopidogrel activation; pantoprazole preferred)

— Tobacco: even one cigarette/day post-MI raises mortality; document 5 A's intervention

— Alcohol, recreational drug use (cocaine, methamphetamine — beta-blocker caution)

— Diet, weight trajectory, physical activity tolerance, sexual activity resumption (safe ~1 week post-uncomplicated MI if able to climb 2 flights without symptoms)

The classic post-discharge encounter (2–4 weeks after index MI)

Symptom-directed history

Medication reconciliation — the highest-yield part of the visit

Lifestyle history

Board pearl: A vignette describing a post-MI patient with fatigue, anhedonia, and missed cardiac rehab sessions is testing post-MI depression — the answer is start an SSRI (sertraline preferred, best CV safety data) and reinforce rehab, not just "encourage exercise."

Key distinction: "Stable" at 2 weeks ≠ optimized. Symptom absence does not justify holding bundle medications.

Physical Exam Findings and Hemodynamic Assessment

— BP goal <130/80 mm Hg (ACC/AHA 2017, reaffirmed for post-MI/CAD)

— Resting HR 55–70 bpm on beta-blocker; bradycardia <50 with symptoms = dose reduction

— Orthostatic vitals if reporting dizziness (common with combined BB + ACEi + diuretic)

— Weight: track trajectory; >2 lb/day or >5 lb/week gain suggests volume overload

— S3 gallop: new HFrEF, predicts adverse remodeling — order repeat echo

— S4: stiff post-infarct ventricle, common and not alarming alone

— New systolic murmur: think post-MI VSD, papillary muscle dysfunction/rupture, or MR — especially if within first 2 weeks

— Pericardial friction rub at 1–3 days = early post-MI pericarditis; at 2–8 weeks = Dressler syndrome

— JVP elevation, hepatojugular reflux, bibasilar crackles, peripheral edema

— Cool extremities + narrow pulse pressure = low output; warrants urgent echo and HF specialist involvement

— Femoral/radial access site (post-cath): bruit, pulsatile mass → pseudoaneurysm; check within 1 week

— Carotid bruits, ABI if symptoms — polyvascular disease drives prognosis

— Skin: petechiae, ecchymoses (DAPT bleeding), xanthelasma (residual lipid risk)

— 6-minute walk or simple stair-climb tolerance guides rehab intensity

— NYHA class documentation at each visit

Vital signs — therapeutic targets, not just numbers

Cardiac exam

Volume assessment

Vascular exam

Functional assessment

CCS pearl: On CCS, a post-MI patient returning with new dyspnea and a holosystolic apical murmur → order STAT echocardiogram and consult cardiology/cardiothoracic surgery; do not simply uptitrate diuretics. Mechanical complications (MR from papillary muscle rupture, VSD, free-wall rupture) peak at days 3–7 but can present up to 2 weeks out.

Board pearl: Resting tachycardia at the post-MI visit in a patient on "max tolerated" metoprolol usually means dose is not actually maximized — uptitrate before adding a second agent.

Diagnostic Workup — Labs, ECG, and Baseline Biomarkers

— Lipid panel: obtain at 4–12 weeks after statin initiation to confirm ≥50% LDL reduction and LDL <70 mg/dL (many guidelines now target <55 mg/dL for very high-risk ASCVD)

— BMP: monitor K+ and Cr at 1–2 weeks after starting/uptitrating ACEi/ARB or MRA; K+ >5.0 or Cr rise >30% triggers dose adjustment

— HbA1c: target individualized, generally <7% post-MI; identifies undiagnosed diabetes

— CBC: baseline Hgb for DAPT bleeding monitoring; anemia (<10 g/dL) raises both ischemic and bleeding risk

— LFTs: baseline for statin; routine repeat not required unless symptomatic

— TSH: amiodarone users, or if new AF

— Lp(a) once in lifetime: ACC 2022 — identifies residual genetic risk; >50 mg/dL = aggressive LDL lowering and consider PCSK9i

— Document baseline post-MI ECG for future comparison

— Watch for: new Q waves, persistent ST elevation (LV aneurysm), QTc prolongation (especially on QT-prolonging agents), conduction disease

— QTc >500 ms: review meds (ondansetron, azithromycin, methadone, antipsychotics)

— Troponin should not be rechecked routinely post-discharge unless new symptoms; baseline may remain mildly elevated for 1–2 weeks

— BNP/NT-proBNP: useful if HF symptoms emerge; not routine screening

— hsCRP persistently >2 mg/L despite LDL <70: signals residual inflammatory risk; colchicine 0.5 mg daily has Class IIb support (LoDoCo2)

Baseline labs at discharge and follow-up

ECG

Cardiac biomarkers

Inflammation/residual risk markers

Step 3 management: At the 2-week post-discharge labs, the highest-yield items are K+, Cr, and a fasting lipid panel. If K+ is 5.3 on lisinopril + spironolactone, reduce the MRA first (greater hyperkalemia driver) rather than stopping the ACEi, which has stronger mortality benefit.

Board pearl: A normal discharge LVEF does not exclude later remodeling. Repeat echo at 40 days post-MI in any patient with initial LVEF ≤40% to assess ICD candidacy.

Diagnostic Workup — Advanced and Confirmatory Studies

— Discharge echo: LVEF, wall motion, valvular function, thrombus screen

— Repeat at 40 days if initial LVEF ≤40% on GDMT — guides primary prevention ICD (LVEF ≤35% and NYHA II–III, or ≤30% and NYHA I)

— Repeat at 3 months for borderline cases — many ventricles recover with GDMT, sparing device implantation

— LV thrombus: anterior MI with apical akinesis — screen with echo; if present, anticoagulate for 3–6 months

— Not routine in asymptomatic patients post-complete revascularization

— Indicated for recurrent symptoms, incomplete revascularization with planned staged intervention, or pre-operative risk assessment

— Choose stress imaging (nuclear, stress echo, CMR) over ECG-only stress when baseline ECG is uninterpretable (LBBB, paced, prior MI)

— Limited role early post-stent (blooming artifact); useful for bypass graft patency or chest pain >6 months post-PCI with low-intermediate pretest probability

— Quantifies infarct size, viability (LGE), and identifies myocardial scar burden predicting VT risk

— Useful when echo is suboptimal or for MINOCA workup (myocarditis, takotsubo, embolic)

— Holter or extended monitor for palpitations, syncope, or unexplained dyspnea

— Post-MI NSVT with LVEF 36–40%: consider EP study for inducibility

— Familial hypercholesterolemia screen if LDL >190 untreated, or family history of premature CAD — cascade test first-degree relatives

Echocardiography — the cornerstone follow-up imaging

Stress testing

Coronary CT angiography

Cardiac MRI

Ambulatory rhythm monitoring

Lipid genetic/extended panel

CCS pearl: On CCS, after anterior STEMI with LVEF 30%, advance the clock to 40 days post-discharge, then order repeat TTE. If LVEF remains ≤35% on optimized GDMT, refer to electrophysiology for ICD — failing to do this loses points.

Board pearl: Wearable cardioverter-defibrillator (LifeVest) bridges the 40–90 day waiting period in selected high-risk patients (e.g., recent revasc with severe LV dysfunction).

Risk Stratification and First-Line Management Logic

— Very high-risk ASCVD (ACC/AHA 2018): recent ACS (<12 months) plus any of — additional MI, ischemic stroke, symptomatic PAD, diabetes, CKD, age ≥65, FH, prior CABG/PCI, HF, current smoking, LDL ≥100 on max statin

— Very high-risk → LDL <55 mg/dL target, add ezetimibe and/or PCSK9 inhibitor without delay

— Standard secondary prevention → LDL <70 mg/dL, high-intensity statin first

— DAPT score or PRECISE-DAPT: high bleeding risk (HBR) shortens DAPT; high ischemic risk extends it

— HBR features: age ≥75, prior bleeding, anemia, CKD, oral anticoagulation, frailty

— Standard ACS post-PCI: 12 months DAPT; HBR may shorten to 1–6 months then aspirin or P2Y12 monotherapy

— LVEF, infarct size, anterior location, diabetes, CKD, AF — drive aggressive RAAS/beta-blocker/MRA/SGLT2i uptitration

— T2DM post-MI: SGLT2 inhibitor (empagliflozin, dapagliflozin) reduces HF hospitalization and CV death — start regardless of A1c if eGFR ≥20

— GLP-1 RA (semaglutide, liraglutide, dulaglutide) reduces MACE — preferred if obesity or A1c off target

— Layer 1 (always): aspirin 81 mg + P2Y12 + high-intensity statin + beta-blocker + ACEi/ARB

— Layer 2 (LVEF ≤40% or HF/diabetes): add MRA (eplerenone/spironolactone)

— Layer 3 (T2DM or HFrEF): add SGLT2i

— Layer 4 (LDL not at goal at 4–6 weeks): add ezetimibe → PCSK9i

— Layer 5 (residual inflammatory risk, hsCRP >2): consider colchicine 0.5 mg daily

Stratify residual risk to drive intensity of therapy

Bleeding risk for DAPT duration

HF risk after MI

Diabetes-specific risk pathway

Step 3 management: Build the discharge order set in layers:

Board pearl: Do not wait for "tolerance" before stacking. Simultaneous initiation of foundational therapies (low doses) outperforms sequential uptitration in HFrEF and post-MI cohorts.

Pharmacotherapy — First-Line Discharge Bundle

— 81 mg daily indefinitely post-MI (lower bleeding than 325 mg, equal efficacy — ADAPTABLE trial)

— Hold only for active bleeding or true allergy (desensitize if needed)

— Ticagrelor 90 mg BID — preferred over clopidogrel after ACS (PLATO); side effects: dyspnea, bradyarrhythmia, hyperuricemia; requires BID adherence and aspirin ≤100 mg

— Prasugrel 10 mg daily — preferred after PCI in ACS without stroke/TIA history; contraindicated if prior stroke/TIA, age ≥75, or weight <60 kg (use 5 mg)

— Clopidogrel 75 mg daily — default if bleeding concerns, on anticoagulation, or unable to afford newer agents; affected by CYP2C19 loss-of-function alleles

— Metoprolol succinate, carvedilol, or bisoprolol — preferred (mortality data in HFrEF)

— Start within 24 hours if hemodynamically stable; continue ≥3 years, indefinitely if LVEF ≤40%

— Avoid acutely in cardiogenic shock, severe bradycardia, high-degree AV block, active bronchospasm

— Lisinopril, ramipril, enalapril — start within 24 h if anterior MI, LVEF ≤40%, HF, diabetes, or HTN

— ARB (losartan, valsartan) if ACEi cough/angioedema

— Sacubitril/valsartan (ARNI) replaces ACEi/ARB in HFrEF post-stabilization (≥36 h washout from ACEi)

— Atorvastatin 40–80 mg or rosuvastatin 20–40 mg — for everyone post-MI regardless of baseline LDL

— Recheck lipids at 4–12 weeks

— Eplerenone or spironolactone if LVEF ≤40% plus HF symptoms or diabetes, and Cr <2.5 (men)/<2.0 (women) and K+ <5.0

Aspirin

P2Y12 inhibitor (12 months standard after ACS)

Beta-blocker

ACE inhibitor / ARB

High-intensity statin

Mineralocorticoid receptor antagonist

Board pearl: A post-ACS patient with prior hemorrhagic stroke → clopidogrel, not prasugrel (absolute contraindication) and avoid ticagrelor caution in active ICH.

Key distinction: Metoprolol tartrate (BID) is acceptable inpatient; switch to succinate (daily) at discharge for HFrEF mortality benefit.

Expanded Pharmacology — Adjuncts and Lipid Intensification

— Add when LDL >70 (or >55 in very high risk) on max-tolerated statin

— Lowers LDL ~20%; IMPROVE-IT showed CV event reduction post-ACS

— Generic, well-tolerated, no monitoring beyond lipids

— SC injection every 2–4 weeks; lower LDL by additional 50–60%

— Indications: ASCVD with LDL ≥70 on max statin + ezetimibe, or FH

— FOURIER and ODYSSEY: significant MACE reduction

— Inclisiran (siRNA): twice-yearly dosing — emerging alternative for adherence

— ATP-citrate lyase inhibitor; useful in statin-intolerant patients

— CLEAR Outcomes: ~13% MACE reduction

— Watch uric acid, tendon rupture risk

— Triglycerides 150–499 on statin with ASCVD → 2 g BID

— REDUCE-IT: 25% MACE reduction

— Caution: increased AF risk

— Now broadly used post-MI with HFrEF, HFpEF, T2DM, or CKD

— EMPACT-MI (2024): empagliflozin post-MI reduced HF hospitalization

— Hold for euglycemic DKA risk during illness/surgery (3 days pre-op)

— MACE reduction in T2DM with ASCVD; semaglutide also benefits non-diabetic obese ASCVD patients (SELECT trial)

— LoDoCo2 and COLCOT: reduces recurrent CV events

— Class IIb; avoid in significant CKD and with strong CYP3A4/P-gp inhibitors

— AF + recent PCI: "triple therapy" ≤1 week, then DOAC + clopidogrel for up to 12 months, then DOAC monotherapy (AUGUSTUS, PIONEER-AF)

— LV thrombus: warfarin or DOAC × 3–6 months with DAPT

Ezetimibe

PCSK9 inhibitors (evolocumab, alirocumab)

Bempedoic acid

Icosapent ethyl (EPA, Vascepa)

SGLT2 inhibitors (empagliflozin, dapagliflozin)

GLP-1 RAs (semaglutide, liraglutide)

Colchicine 0.5 mg daily

Nitrates / ranolazine: symptom relief only, no mortality benefit; reserve for refractory angina

Anticoagulant + DAPT scenarios

Step 3 management: When stacking ARNI + MRA + SGLT2i + beta-blocker post-MI with HFrEF, start all four at low doses simultaneously, recheck K+/Cr at 1–2 weeks, then uptitrate biweekly to target or max tolerated.

Board pearl: Never combine ARNI with ACEi — 36-hour washout required to avoid angioedema.

Special Populations — Elderly and Renal/Hepatic Impairment

— Bundle still applies — undertreatment is the dominant error on Step 3 vignettes

— Start at lower doses, uptitrate slowly; monitor orthostasis, falls, cognition

— Prasugrel contraindicated ≥75 (except diabetes or prior MI per labeling); ticagrelor or clopidogrel preferred

— High bleeding risk: consider shortened DAPT (1–6 months) then P2Y12 monotherapy

— Beta-blockers: watch for symptomatic bradycardia, AV block

— Statins: continue high-intensity; if intolerant, moderate-intensity acceptable

— All bundle drugs are still indicated; adjust doses, do not omit

— ACEi/ARB: continue unless K+ >5.5 or Cr rise >30% — small Cr rises are expected and acceptable

— MRA: avoid if eGFR <30 or K+ >5.0; use eplerenone if gynecomastia issue

— SGLT2i: now approved down to eGFR ≥20; benefit persists

— Atorvastatin preferred (no renal dose adjustment); rosuvastatin requires dose reduction <30

— Clopidogrel preferred over ticagrelor/prasugrel in severe CKD/dialysis (limited trial data with newer agents)

— Avoid NSAIDs, contrast when feasible

— Statin benefit limited if started after dialysis initiation (4D, AURORA) but continue if already on

— DAPT decisions individualized; high bleeding risk

— Ticagrelor and prasugrel: avoid in severe hepatic impairment

— Statins: avoid in active liver disease/decompensated cirrhosis; compensated NAFLD/NASH is not a contraindication — statins are safe and beneficial

— Monitor LFTs only if symptoms

— Use a frailty index or gait speed; deprescribe selectively, never reflexively

— Polypharmacy review at each visit; align with goals of care

Elderly (≥75 years)

CKD (eGFR <60)

ESRD / dialysis

Hepatic impairment

Frailty

Step 3 management: A 78-year-old post-NSTEMI with eGFR 35, prior GI bleed, and AF — discharge on apixaban + clopidogrel (drop aspirin after 1 week), atorvastatin 40, metoprolol succinate, lisinopril low dose, hold MRA given CKD/K+ proximity.

Board pearl: Age alone is never a reason to withhold statin or beta-blocker post-MI.

Special Populations — Pregnancy, Women, and Other Subgroups

— Pregnancy-associated MI: often SCAD (spontaneous coronary artery dissection) — peripartum, especially postpartum week 1–2

— Contraindicated in pregnancy/lactation: ACEi, ARB, ARNI, statins (relative — recent FDA label update removed absolute contraindication but generally avoided), spironolactone (anti-androgen)

— Safe: low-dose aspirin, metoprolol/labetalol, clopidogrel (limited data, use if essential), heparin/LMWH

— Counsel on contraception during high-risk medication use; avoid combined estrogen contraceptives post-MI (thrombotic risk) — use progestin-only or IUD

— More likely to have MINOCA, SCAD, microvascular disease

— Underprescribed bundle therapy historically — explicitly verify each component

— Higher bleeding risk on DAPT; consider weight-based prasugrel dose if <60 kg

— Cardiac rehab referral rates lower in women — actively refer

— Workup: CMR, IVUS/OCT for plaque erosion, vasospasm provocation testing

— Treat the underlying mechanism — atherosclerotic MINOCA gets the full bundle; takotsubo gets BB + ACEi until recovery; vasospasm gets CCB + nitrates, avoid nonselective BB

— Conservative management preferred over PCI when stable

— Avoid stenting unless ongoing ischemia

— DAPT duration controversial — many use aspirin + clopidogrel × 1 year, then aspirin

— Screen for fibromuscular dysplasia (head-to-pelvis CTA/MRA)

— Avoid intense isometric exercise, pregnancy counseling

— Avoid nonselective beta-blockers in acute setting (unopposed alpha)

— Long-term: carvedilol or labetalol acceptable; abstinence counseling is the cornerstone

— Screen for FH, Lp(a), thrombophilia, substance use, HIV, autoimmune disease

Pregnancy and post-MI

Women

MINOCA (MI with non-obstructive coronaries)

SCAD

Cocaine/methamphetamine-associated MI

Young patients (<55)

Board pearl: Postpartum woman with chest pain and troponin elevation → think SCAD first; coronary angiography is diagnostic, and management is usually medical, not stent.

Complications and Adverse Outcomes of the Bundle and Disease

— Most common: GI bleeding — co-prescribe PPI (pantoprazole preferred with clopidogrel) for high-risk patients

— Intracranial hemorrhage: rare but devastating; ticagrelor and prasugrel slightly higher than clopidogrel

— Management of major bleed: hold antiplatelets, transfuse, identify source; resume as soon as hemostasis secure — withholding too long causes stent thrombosis

— Early (<30 days): often due to premature DAPT discontinuation — medical emergency, presents as STEMI

— Late (>1 year): consider DES-related neoatherosclerosis

— Prevention: never stop DAPT prematurely without cardiology input; coordinate with surgical teams

— Statins: myalgias (5–10%), rhabdomyolysis (rare), transaminitis, new-onset diabetes (small absolute risk, benefit outweighs)

— ACEi: cough (10–20%), angioedema, hyperkalemia, AKI

— MRA: hyperkalemia, gynecomastia (spironolactone)

— Ticagrelor: dyspnea (~15%), bradycardia, hyperuricemia

— SGLT2i: euglycemic DKA, genitourinary infections, volume depletion, rare Fournier's gangrene

— Beta-blockers: fatigue, bradycardia, erectile dysfunction, masking of hypoglycemia

— Post-MI HFrEF: 20–40% develop LV dysfunction; aggressive GDMT

— Ventricular arrhythmias: monitor with rhythm strips; ICD if LVEF ≤35% at 40 days

— LV aneurysm/thrombus: anticoagulate

— Dressler syndrome (2–8 weeks): pleuritic chest pain, fever, pericardial rub — treat with high-dose aspirin or colchicine; avoid NSAIDs and steroids (impair healing)

— Recurrent ischemia/MI: re-evaluate adherence, completeness of revascularization

Bleeding complications (DAPT-related)

Stent thrombosis

Drug-specific adverse effects

Disease-related complications

Step 3 management: Post-MI patient on DAPT with melena — admit, transfuse to Hgb >7 (>8 if ongoing ischemia), urgent EGD, hold P2Y12 (keep aspirin if possible), restart P2Y12 within 5–7 days after hemostasis. Lifelong PPI thereafter.

Board pearl: "Statin myalgias" with normal CK and resolution off drug: rechallenge with different statin or alternate-day dosing, then add ezetimibe/PCSK9i.

When to Escalate — ICU, Consults, and Readmission Triggers

— Recurrent chest pain at rest or with minimal exertion — rule out stent thrombosis, reinfarction

— Syncope or sustained palpitations — possible VT, AV block

— Acute dyspnea, orthopnea, weight gain >5 lb in a week — decompensated HF

— Major bleeding — GI, intracranial, hemodynamically significant

— New focal neurologic deficit — stroke (cardioembolic from LV thrombus, AF, or hemorrhagic from DAPT)

— Cardiogenic shock — vasopressors, inotropes, mechanical support (IABP, Impella, VA-ECMO)

— Sustained VT/VF — antiarrhythmics, defibrillation, EP consult

— Mechanical complications (VSD, papillary muscle rupture, free wall rupture) — emergent surgery

— Cardiology at 2–4 weeks routinely; sooner for symptoms, LVEF ≤40%, complex anatomy

— Electrophysiology: LVEF ≤35% at 40 days, NSVT, syncope, conduction disease

— Heart failure specialist: advanced HF, intolerance of GDMT, transplant/LVAD eval if LVEF <25% with refractory symptoms

— Cardiac surgery: mechanical complications, multivessel disease not amenable to PCI, severe valvular disease

— Lipidology/Endocrinology: refractory dyslipidemia, suspected FH, complex diabetes

— Mental health: PHQ-9 ≥10, suicidal ideation, severe adjustment disorder

— Palliative care: refractory symptoms, advanced HF, goals-of-care clarification

— Transition-of-care visit within 7–14 days for post-MI — strong evidence reduces 30-day readmission

— Pharmacist-led medication reconciliation

— Patient teach-back on red flags

Immediate ED/admission triggers post-discharge

ICU-level care

Consult triggers (outpatient)

Readmission risk reduction (CMS measure)

CCS pearl: Post-MI patient calls at home with substernal chest pain × 2 hours, diaphoresis, on day 5 post-DES — on CCS, advance to EMS activation, give chewable aspirin 325 mg, send to ED, order ECG and troponin stat, alert interventional cardiology for possible repeat cath. Do not schedule outpatient stress test — this is acute stent thrombosis until proven otherwise.

Board pearl: A missed 7–14 day post-discharge follow-up is a national quality metric and a frequent Step 3 stem error.

Key Differentials — Same-Category (Cardiovascular) Causes of Recurrent Symptoms

— In-stent restenosis (months to 1 year post-PCI, especially BMS)

— Stent thrombosis (early <30 d = mechanical/DAPT issue; late = neoatherosclerosis)

— Progression of nontreated coronary lesions

— Bypass graft failure (vein grafts: ~10%/year occlusion)

— Ischemic remodeling with worsening LVEF

— Dietary/medication nonadherence

— Uncontrolled HTN, AF with RVR

— Post-infarct VT (scar-related reentry) — peak 3–12 months

— New AF — common, drives anticoagulation decisions (CHA₂DS₂-VASc; post-MI alone scores 1)

— Bradyarrhythmias from beta-blocker, inferior MI–related AV block

— Early post-MI pericarditis (days 1–3): localized, treat with high-dose aspirin

— Dressler syndrome (weeks 2–8): autoimmune; aspirin or colchicine first-line

— Avoid NSAIDs and corticosteroids in either — impair myocardial healing

— Papillary muscle rupture → acute severe MR, flash pulmonary edema

— VSD → new harsh holosystolic murmur, RV failure

— Free wall rupture → tamponade, PEA arrest

— Aortic dissection mimics recurrent MI; tearing pain, BP differential

— Severe aortic stenosis presenting with angina post-MI workup

— Especially in women, MINOCA workup, postmenopausal

— Diagnosis: provocation testing; treatment CCB + nitrates, avoid nonselective BB

Recurrent angina/MI

Heart failure exacerbation

Arrhythmias

Pericardial syndromes

Mechanical complications (days 3–14)

Aortic disease

Vasospasm / microvascular angina

Key distinction: Early post-MI pericarditis (focal, days 1–3) vs Dressler syndrome (systemic, weeks 2–8 with effusion and labs of inflammation) vs recurrent ischemia (exertional, ECG dynamic changes, troponin re-rise) — exam cadence, ECG (diffuse ST elevation vs regional), and timing differentiate.

Board pearl: Any post-MI patient with PEA arrest 3–7 days out → suspect free wall rupture with tamponade; bedside echo and emergent surgical consult.

Key Differentials — Other-Category (Non-CV) Causes of Post-MI Symptoms

— PE: post-procedure immobility, hypercoagulability — sudden dyspnea, hypoxia, tachycardia; check d-dimer/CTPA

— Pneumonia: especially in elderly, low ambulation post-MI

— COPD exacerbation: beta-blocker tolerance issue (cardioselective BBs are safe)

— Pleural effusion (Dressler-associated)

— Aspirin/DAPT-induced GI bleeding presenting as fatigue, dyspnea (anemia), or syncope

— PUD, gastritis — co-prescribe PPI in high-risk patients

— Acute cholecystitis, pancreatitis mimicking chest pain

— Costochondritis from prolonged bed rest, post-PCI positioning

— Post-sternotomy pain after CABG — distinguish from angina by reproducibility on palpation

— Post-MI depression and anxiety: PHQ-9 ≥10 in 20–30% of post-MI patients

— Panic disorder mimicking angina — but always rule out cardiac cause first in this population

— PTSD from cardiac arrest survival

— Hypothyroidism unmasked or worsened (amiodarone, statin-related fatigue mimicker)

— Hypoglycemia from intensified diabetes regimen — masked by beta-blockers

— Adrenal insufficiency (rare, but consider in refractory hypotension)

— Contrast-induced AKI post-cath — typically transient, peaks day 3–5

— Worsening CKD from ACEi/ARB + diuretic combinations

— Anemia from DAPT bleeding or chronic disease

— Thrombocytopenia: HIT (recent heparin exposure), drug-induced

— Endocarditis (especially if recent procedures/access)

— Access site infection — femoral or radial

Pulmonary

Musculoskeletal

Psychiatric

Endocrine/Metabolic

Renal

Hematologic

Infectious

Step 3 management: Post-MI patient at 2-week visit with dyspnea, leg swelling, sinus tachycardia, normal BNP — do not reflexively uptitrate HF therapy. Calculate Wells score, get d-dimer/CTPA — PE is a classic post-discharge masquerader.

Board pearl: Fatigue + dyspnea + Hgb drop from 13 to 9 in a post-MI patient on aspirin + ticagrelor → occult GI bleed, not HF.

Secondary Prevention / Discharge Bundle — The Definitive Checklist

— Aspirin 81 mg daily — indefinite

— P2Y12 inhibitor (ticagrelor/prasugrel preferred; clopidogrel if HBR or on AC) — 12 months standard; individualize

— High-intensity statin (atorva 40–80 or rosuva 20–40) — indefinite; goal LDL <70 (<55 if very high risk)

— Beta-blocker — at least 3 years; indefinite if LVEF ≤40%

— ACEi/ARB — indefinite if anterior MI, LVEF ≤40%, HF, diabetes, HTN, or CKD

— MRA — if LVEF ≤40% plus HF symptoms or diabetes, and K+/Cr permit

— SGLT2 inhibitor — if T2DM, HFrEF, HFpEF, or CKD; consider broadly post-MI

— Sublingual nitroglycerin — PRN for chest pain with action plan

— Influenza vaccine annually, pneumococcal per schedule, COVID-19 boosters — reduce CV events

— PPI if high GI bleed risk on DAPT

— Smoking cessation: counseling + varenicline or nicotine replacement; bupropion if depression coexists

— Mediterranean or DASH diet

— Exercise: 150 min/week moderate aerobic + resistance training 2×/week (after rehab clearance)

— Weight: BMI goal <25; waist <40 in (M) / <35 in (F)

— Alcohol: ≤1 drink/day women, ≤2 men; less is better

— Sleep: screen for OSA — STOP-BANG; CPAP if moderate-severe

— Influenza shown to reduce post-MI MACE (IAMI trial)

— Document at discharge

— Class I indication post-MI/PCI/CABG; 36 sessions over 12 weeks typically

— Reduces mortality ~20–25%, improves QoL, increases adherence

— Refer at discharge — automatic referral order set is best practice

— Home-based and hybrid rehab now Medicare-covered alternatives

The complete post-MI discharge bundle (memorize)

Lifestyle bundle

Vaccinations as secondary prevention

Cardiac rehabilitation

Step 3 management: On the discharge order screen, the single highest-yield missed item is cardiac rehab referral — always check the box. Second highest: influenza vaccine if not already given.

Board pearl: Hormone replacement therapy is NOT cardioprotective and is contraindicated for secondary prevention in postmenopausal women with CAD.

Follow-Up, Monitoring Parameters, and Rehab/Counseling

— 7–14 days post-discharge: PCP or cardiology transition visit — medication reconciliation, symptom review, labs (K+, Cr), depression screen

— 4–6 weeks: cardiology — repeat lipid panel, uptitrate GDMT

— 3 months: full reassessment, consider repeat echo if initial LVEF reduced

— 6 and 12 months: ongoing optimization, decide on DAPT duration extension/discontinuation

— Annually thereafter with cardiology and PCP

— BP every visit; home BP log encouraged

— HR for beta-blocker titration

— Weight for HF surveillance

— Lipid panel at 4–12 weeks, then annually

— BMP 1–2 weeks after starting/uptitrating ACEi/ARB/MRA, then every 3–6 months

— HbA1c every 3 months until at goal, then every 6 months

— CBC annually or with symptoms

— LFTs at baseline; repeat only if symptoms

— Phase I: inpatient — early mobilization

— Phase II: outpatient supervised — 36 sessions, monitored exercise, education, risk-factor modification

— Phase III/IV: maintenance — lifelong activity

— Document attendance — nonadherence triggers re-engagement

— Driving: typically resume after 1 week if uncomplicated MI; commercial driving has stricter requirements (varies by state — DOT certification often delayed 2 months)

— Sexual activity: safe ~1 week post-uncomplicated MI; PDE5 inhibitors contraindicated with any nitrate use (24 h sildenafil, 48 h tadalafil)

— Return to work: typically 1–2 weeks for sedentary jobs, 2–4+ for physical labor

— Travel: avoid commercial flight ×2 weeks post-uncomplicated MI; longer if complicated

— Depression: PHQ-9 at every visit in year 1

Follow-up cadence

Monitoring parameters

Cardiac rehabilitation specifics

Counseling priorities

Step 3 management: Post-MI patient returns at 6 weeks: BP 142/88, LDL 92, HR 78, LVEF 38% on echo. Actions: uptitrate beta-blocker (HR target <70), uptitrate ACEi or add ezetimibe (BP and LDL both off goal), add MRA (LVEF ≤40%), reinforce rehab, schedule 40-day echo for ICD evaluation.

Board pearl: Door-to-rehab time matters — referral within 10 days of discharge dramatically improves enrollment.

Ethical, Legal, and Patient Safety Considerations

— DAPT duration is a shared decision — discuss bleeding vs ischemic trade-offs explicitly; document the conversation

— ICD implantation at 40 days with LVEF ≤35%: discuss mortality benefit, device complications, end-of-life deactivation — many patients decline; that is a valid informed choice

— PCSK9i/expensive therapy: discuss cost, coverage, alternatives transparently

— Medication reconciliation errors are the leading cause of post-discharge adverse events

— Use teach-back: have patient name each medication, indication, and dose before discharge

— Communicate clearly with PCP within 48 hours — discharge summary should specify DAPT duration, follow-up plan, pending labs, and any deviations from standard bundle

— Pillbox or blister packs for polypharmacy/low health literacy

— Commercial drivers (CDL): federal DOT rules — typically off-duty ≥2 months post-MI with documentation of LVEF ≥40% and negative stress test

— Pilots, public transit operators, heavy machinery: similar restrictions, often longer

— Document counseling explicitly

— Some states require reporting of conditions affecting driving (syncope, ICD shocks)

— Document any decline of recommended therapy after informed counseling

— P2Y12 inhibitors and PCSK9i have substantial out-of-pocket costs — screen for cost-related nonadherence at every visit; use patient assistance programs

— Cardiac rehab disparities by race, sex, geography, and insurance — actively advocate

— Post-MI with severe LV dysfunction: introduce advance care planning early

— ICD deactivation conversations at end of life — coordinate with EP and palliative care; this is not PAS or euthanasia and is ethically supported

— A patient with capacity may refuse any therapy; document understanding, attempt alternatives, do not coerce; reassess at next visit

Informed consent and shared decision-making

Transition-of-care safety (a Step 3 favorite)

Driving and occupational safety

Mandatory reporting and physician duty

Health equity and access

End-of-life and goals of care

Capacity and refusal

Board pearl: A post-MI patient says he "doesn't want pills" but agrees to rehab — meet him where he is, prioritize the highest-impact agent (aspirin + statin), document shared decision, and revisit.

Step 3 management: Always confirm two-way communication with the receiving PCP within 48 hours of discharge — this is a measurable safety standard and a frequent test point.

High-Yield Associations and Rapid-Fire Clinical Facts

— Aspirin → ACEi/ARB → statin → beta-blocker → P2Y12 → MRA (if LVEF ≤40%) → SGLT2i → cardiac rehab → smoking cessation (single largest single-intervention mortality reduction)

— Standard: 12 months post-ACS

— HBR shortened: 1–6 months then monotherapy

— Extended (DAPT score ≥2): up to 30 months in selected patients

— Stop 5–7 days before elective non-cardiac surgery (clopidogrel); 3–5 days ticagrelor; 7 days prasugrel; aspirin continued through most surgeries except neurosurgery and select procedures

— Very high-risk ASCVD: LDL <55 mg/dL

— Standard secondary prevention: <70 mg/dL

— Recheck 4–12 weeks after initiation/change

— Wait 40 days post-MI (or 90 days post-revascularization) before primary prevention ICD assessment

— LVEF ≤35% NYHA II–III, or ≤30% NYHA I

— Early: aspirin high-dose (650–1000 mg q6h), avoid NSAIDs/steroids

— Dressler: aspirin or colchicine

— Influenza annually (Class I post-MI)

— Pneumococcal, COVID-19

— Triple ≤1 week → DOAC + clopidogrel × up to 12 months → DOAC monotherapy

— Apixaban preferred for bleeding profile

— Anterior STEMI + apical akinesis → screen with echo; if present, anticoagulate 3–6 months

— Resume ~1 week if can climb 2 flights of stairs symptom-free

— Nitrate + PDE5i = absolute contraindication

— Quitting reduces 1-year mortality by ~36%

— Varenicline + behavioral support most effective

Mortality benefit hierarchy post-MI (memorize)

DAPT key numbers

Statin targets

ICD timing

Pericarditis after MI

Vaccines reducing MACE

AF + post-PCI cocktail (default)

LV thrombus

Sexual activity safety

Smoking cessation post-MI

Board pearl: The single biggest mortality-reducing intervention you can offer a smoker post-MI is tobacco cessation — bigger than any individual pill. Always pair pharmacotherapy with counseling.

Key distinction: Aspirin dose post-MI is 81 mg daily — higher doses bleed more without added benefit.

Board Question Stem Patterns

— "55-year-old man discharged 4 weeks ago after NSTEMI with PCI of LAD. Meds: aspirin 81, atorvastatin 40, metoprolol succinate 50. LVEF 35%. BP 128/78. K+ 4.2, Cr 1.0. Next best step?"

— Answer: Add lisinopril and a P2Y12 inhibitor (he's missing both); also add MRA given LVEF ≤40%

— "Post-MI patient on atorvastatin 80 for 3 months. LDL 88. Next step?"

— Answer: Add ezetimibe; if still >70 after 4–6 weeks, PCSK9 inhibitor

— Post-PCI on aspirin + ticagrelor, presents with melena and Hgb 8. Next step?

— Answer: Admit, transfuse if Hgb <7–8, EGD, hold P2Y12 temporarily (continue aspirin if possible), restart P2Y12 within 5–7 days, add PPI

— Anterior MI, LVEF 30% on discharge. Returns at 6 weeks, LVEF still 30% on max GDMT. Next step?

— Answer: Refer for primary prevention ICD evaluation

— Postpartum day 10, severe chest pain, troponin elevated. Best test?

— Answer: Coronary angiography to evaluate for SCAD; management usually conservative

— T2DM, A1c 7.8%, post-MI 3 months ago, eGFR 65. Already on metformin. Next add?

— Answer: SGLT2 inhibitor (or GLP-1 RA if obesity); both reduce MACE

— Post-MI patient at 2 weeks, fully optimized meds, no rehab referral made. Best next step?

— Answer: Refer to cardiac rehabilitation — Class I indication, frequently tested

— PHQ-9 of 14 at 6-week visit, missed rehab sessions. Best initial treatment?

— Answer: Sertraline + continued rehab engagement; safest SSRI in CV disease

— Day 5 post-MI, new harsh holosystolic murmur, hypotension. Diagnosis and next step?

— Answer: Post-MI VSD; emergent echo + cardiothoracic surgery consult

— AF + recent PCI on aspirin, clopidogrel, apixaban. Next step at 1 week?

— Answer: Drop aspirin, continue clopidogrel + apixaban up to 12 months

Stem 1 — The incomplete discharge bundle

Stem 2 — The lipid target miss

Stem 3 — The DAPT-bleeding patient

Stem 4 — The 40-day ICD timing

Stem 5 — The pregnancy/postpartum chest pain

Stem 6 — The diabetic post-MI patient

Stem 7 — The cardiac rehab miss

Stem 8 — Post-MI depression

Stem 9 — The mechanical complication

Stem 10 — Triple therapy duration

Board pearl: When the stem lists meds and asks "what's missing?" — run the bundle: A-B-C-D-E. The omitted letter is the answer.

One-Line Recap

Every post-MI patient leaves the hospital on aspirin, a P2Y12 inhibitor, a high-intensity statin, a beta-blocker, and an ACEi/ARB — with an MRA and SGLT2 inhibitor layered in for reduced LVEF or diabetes, lipid intensification to LDL <70 (or <55 if very high risk), cardiac rehab referral, smoking cessation, depression screening, and a 7–14 day transition visit — and stays on this bundle for life unless a specific contraindication develops.

Bundle in one breath: Aspirin 81 + P2Y12 × 12 months + high-intensity statin + beta-blocker + ACEi/ARB + (MRA if EF ≤40%) + (SGLT2i if DM/HF) + cardiac rehab + smoking cessation + flu vaccine.

Numbers to memorize: LDL <70 (very high risk <55); BP <130/80; HR 55–70; DAPT 12 months standard; ICD reassessment 40 days; transition visit 7–14 days; lipid recheck 4–12 weeks; cardiac rehab 36 sessions.

Mortality reducers ranked: Smoking cessation > aspirin > statin > ACEi/ARB > beta-blocker > P2Y12 > MRA > SGLT2i > cardiac rehab — but the stack is greater than any single component, and the discharge encounter is the single highest-leverage clinical moment.

Step 3 traps: Forgetting cardiac rehab referral, omitting MRA when LVEF ≤40%, holding ACEi for small Cr bumps, missing PHQ-9, prescribing prasugrel after stroke, combining ARNI with ACEi, not adjusting clopidogrel-PPI choice (use pantoprazole), failing to set DAPT stop date, and skipping the 7–14 day transition-of-care visit.

CCS pearl: On the discharge screen, check every bundle component plus rehab plus follow-up appointment before ending the case — a single omission can cost a meaningful fraction of the score, and these are the exact items that change long-term mortality in the real world.